TREK channel activation suppresses migraine pain phenotype
Pablo Ávalos Prado, Arnaud Landra-Willm, Clément Verkest, Aurore Ribera, Anne‐Amandine Chassot, Anne Baron, Guillaume Sandoz
Abstract
) channels inhibits TG neuronal firing sufficiently to fully reverse the migraine-like phenotype induced by NO-donors in rodents. Finally, targeting TREK is as efficient as treatment with CGRP antagonists, which represents one of the most effective migraine therapies. Altogether, our results demonstrate that inhibiting TG excitability by pharmacological activation of TREK channels should be considered as an alternative to the current migraine treatment.
Topics & Concepts
MigraineCalcitonin gene-related peptidePotassium channelNeuroscienceIn vivoCalcitoninPharmacologyChemistryPhenotypeSensitizationMedicineCortical spreading depressionTrigeminal ganglionSensory systemNeuropeptideBiologyInternal medicineGeneReceptorBiochemistryGeneticsMigraine and Headache StudiesNeuroscience of respiration and sleepNicotinic Acetylcholine Receptors Study